Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2014 · 10-Q
Revenue$111.00K$111.00K−6.7% vs Q1 2013 Net Income-$3.19M-$3.19MN/M vs Q1 2013 EPS Diluted-$0.17-$0.17N/M vs Q1 2013 Operating Income-$3,259,638N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,917,178N/M Margins · derivedOperating margin-2936.6%−928.3 pt vs Q1 2013
Net margin-2873.7%−1940.3 pt vs Q1 2013
ended Mar 31, 2014 · filed May 12, 2014 · 42 d after period end